X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protection.
Lead Product(s): Rifampicin,Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: CanGaroo RM
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Berkeley Biologics
Deal Size: $35.0 million Upfront Cash: $35.0 million
Deal Type: Divestment November 09, 2023
Details:
The net proceeds will support the Company’s advancement of its drug-eluting biomatrix products, including CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protection.
Lead Product(s): Rifampicin,Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: CanGaroo
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: HighCape Capital
Deal Size: $26.2 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 19, 2023
Details:
Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protection.
Lead Product(s): Rifampicin,Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: CanGaroo
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Berkeley Biologics
Deal Size: $35.0 million Upfront Cash: $35.0 million
Deal Type: Divestment September 18, 2023
Details:
Citius intends to use the net proceeds for pre-clinical and clinical development of its product candidates, including Mino-Wrap, a malleable, bio-absorbable film impregnated with minocycline and rifampin used in patients that elect to undergo reconstructive breast surgery.
Lead Product(s): Minocycline Hydrochloride,Rifampicin
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Wrap
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 04, 2023
Details:
CanGaroo RM Antibacterial Envelope contains the antibiotics rifampin and minocycline, which have been shown in preclinical testing to reduce bacterial colonization on the envelope.
Lead Product(s): Rifampicin,Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: CanGaroo
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
Mino-Wrap is a liquefying gel-based wrap containing minocycline and rifampin for reducing tissue expander infections following breast reconstructive surgeries. Some next steps for Mino-Wrap development include designing and executing a large animal study and the clinical plan.
Lead Product(s): Minocycline Hydrochloride,Rifampicin
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Wrap
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Details:
Research found that eight-week course of the proven leprosy drug dapsone combined with doxycycline and rifampin is effective in improving symptoms in 98% of patients suffering from chronic Lyme disease/Post Treatment Lyme Disease Syndrome (PTLDS).
Lead Product(s): Dapsone,Doxycycline,Rifampicin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Details:
Mino-Wrap is a novel approach to reducing post-operative infections associated with surgical implants. Mino-Wrap is a liquefying gel-based wrap containing minocycline and rifampin for reducing tissue expander (TE) infections following breast reconstructive surgeries.
Lead Product(s): Minocycline Hydrochloride,Rifampicin
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Wrap
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
